DLA Piper advised Axsome Therapeutics on the deal. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics’ License Agreement with Pharmanovia
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...